Curated News
By: NewsRamp Editorial Staff
June 23, 2026

HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch to Detect Ischemia

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • HeartBeam's new patch could disrupt the $2 billion cardiac monitoring market by offering on-demand 12-lead ECG.
  • HeartBeam launched a pilot study to evaluate its 12-lead ECG patch for detecting coronary artery disease and ischemia.
  • This technology could enable earlier detection of heart disease, potentially saving millions of lives annually.
  • Unlike current patches, HeartBeam's device can generate on-demand 12-lead ECGs, a first for ambulatory monitors.

Impact - Why it Matters

This matters because coronary artery disease is a leading cause of death globally, often undetected until a heart attack occurs. HeartBeam's patch could revolutionize early detection of ischemia, potentially saving lives by enabling timely intervention. If proven effective, it may transform cardiac monitoring from clinic-based to accessible, continuous home use, reducing healthcare costs and improving patient outcomes.

Summary

LOS ANGELES, CA - June 23, 2026 - Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam (NASDAQ: BEAT) has launched a new pilot study designed to evaluate its technology - a proprietary on-demand 12-lead ECG patch - in detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, or ischemia. The seriousness of coronary artery disease continues to intensify as populations age and cardiovascular risk factors become more common.

HeartBeam announced the launch of a pilot study focused on evaluating its on-demand 12-lead ECG patch in detecting coronary artery disease and ischemia. The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (“MCT”) markets. “Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could revolutionize how we monitor and diagnose heart disease.” The pilot study will enroll patients at multiple clinical sites, and results are expected to provide critical data on the patch's accuracy and usability.

This development is particularly significant because current patch-based monitors cannot detect ischemia, a key indicator of coronary artery disease. If successful, HeartBeam's technology could offer a non-invasive, patient-friendly approach to continuous cardiac monitoring, potentially reducing the need for more invasive procedures and enabling earlier interventions. The company's newsroom provides the latest updates, and the full terms of use and disclaimers are available on the InvestorBrandNetwork website. This news was originally published on NEWMEDIAWIRE.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch to Detect Ischemia

blockchain registration record for this content.